Impact of a clinical pharmacy program on changes in hemoglobin A1c, diabetes-related hospitalizations, and diabetes-related emergency department visits for patients with diabetes in an underserved population

Journal of Managed Care Pharmacy

Volumn 20, Issue 9, 2014, Pages 914-919

  Chung, Nancy ^a   Rascati, Karen ^b   Lopez, Debra ^b   Jokerst, Jason ^c   Garza, Aida ^c  

^a UNIVERSITY OF HOUSTON   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^c Clinical Pharmacist at CommUnityCare   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL PHARMACY; CONTROLLED STUDY; DIABETIC PATIENT; EMERGENCY HEALTH SERVICE; EMERGENCY WARD; FEMALE; HEMOGLOBIN BLOOD LEVEL; HOSPITALIZATION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MEDICALLY UNDERSERVED; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PHARMACIST; POPULATION RESEARCH; PROGRAM IMPACT; RETROSPECTIVE STUDY; ADOLESCENT; BLOOD; COHORT ANALYSIS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FOLLOW UP; HEALTH CENTER; HYPOGLYCEMIA; MIDDLE AGED; PHARMACY; UNITED STATES; VERY ELDERLY; VULNERABLE POPULATION; YOUNG ADULT; DIABETES MELLITUS; EMERGENCY CARE; GLYCEMIC CONTROL; PHARMACEUTICAL CARE; PROPENSITY SCORE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; COMMUNITY HEALTH CENTERS; COMMUNITY PHARMACY SERVICES; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; EMERGENCY SERVICE, HOSPITAL; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HOSPITALIZATION; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TEXAS; VULNERABLE POPULATIONS; YOUNG ADULT;

EID: 84906097637     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2014.20.9.914     Document Type: Article

References (22)

1. U.S. Centers for Disease Control and Prevention. National diabetes fact sheet, 2011. Available at: http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011. pdf. Accessed June 11, 2014.
2. American Diabetes Association. Economic costs of diabetes in the U.S. in 2012. Diabetes Care. 2013;36(4):1033-46.
3. American Diabetes Association. Economic costs of diabetes in the U.S. in 2007. Diabetes Care. 2008;31(3):596-615.
4. Jiang HJ, Stryer D, Friedman B, Andrews R. Multiple hospitalizations for patients with diabetes. Diabetes Care. 2003;26(5):1421-26.
5. Hammond RW, Schwartz AH, Campbell MJ, et al. Collaborative drug therapy management by pharmacists-2003. Pharmacotherapy. 2003;23(9):1210-25.
6. Chisholm-Burns MA, Graff Zivin JS, Lee JK, et al. Economic effects of pharmacists on health outcomes in the United States: a systematic review. Am J Health Syst Pharm. 2010;67(19):1624-34.
7. Cranor CW, Bunting BA, Christensen DB. The Asheville Project: longterm clinical and economic outcomes of a community pharmacy diabetes care program. J Am Pharm Assoc (Wash). 2003;43(2):173-84.
8. Anaya JP, Rivera JO, Lawson K, Garcia J, Luna J Jr, Ortiz M. Evaluation of pharmacist-managed diabetes mellitus under a collaborative drug therapy agreement. Am J Health Syst Pharm. 2008;65(19):1841-45.
9. Sease JM, Franklin MA, Gerrald KR. Pharmacist management of patients with diabetes mellitus enrolled in a rural free clinic. Am J Health Syst Pharm. 2013;70(1):43-47.
10. Ip EJ, Shah BM, Yu J, Nguyen LT, Bhatt DC. Enhancing diabetes care by adding a pharmacist to the primary care team. Am J Health Syst Pharm. 2013;70(10):877-86.
11. Johnson KA, Chen S, Cheng IN, et al. The impact of clinical pharmacy services integrated into medical homes on diabetes-related clinical outcomes. Ann Pharmacother. 2010;44(12):1877-86.
12. Choe HM, Mitrovich S, Dubay D, Hayward RA, Krein SL, Vijan S. Proactive case management of high-risk patients with type 2 diabetes mellitus by a clinical pharmacist: a randomized controlled trial. Am J Manag Care. 2005;11(4):253-60.
13. Coast-Senior EA, Kroner BA, Kelley CL, Trilli LE. Management of patients with type 2 diabetes by pharmacists in primary care clinics. Ann Pharmacother. 1998;32(6):636-41.
14. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet. 1998;352(9131):837-53.
15. Menzin J, Korn JR, Cohen J, et al. Relationship between glycemic control and diabetes-related hospital costs in patients with type 1 or type 2 diabetes mellitus. J Manag Care Pharm. 2010;16(4):264-75. Available at: http://www. amcp.org/WorkArea/DownloadAsset.aspx?id=8334.
16. Turnbull FM, Abraira C, Anderson RJ, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia. 2009;52(11):2288-98.
17. Kiel PJ, McCord AD. Pharmacist impact on clinical outcomes in a diabetes disease management program via collaborative practice. Ann Pharmacother. 2005;39(11):1828-32.
18. Scott DM, Boyd ST, Stephan M, Augustine SC, Reardon TP. Outcomes of pharmacist-managed diabetes care services in a community health center. Am J Health Syst Pharm. 2006;63(21):2116-22.
19. Cook CB, Naylor DB, Hentz JB, et al. Disparities in diabetes-related hospitalizations: relationship of age, sex, and race/ethnicity with hospital discharges, lengths of stay, and direct inpatient charges. Ethn Dis. 2006;16(1):126-31.
20. Davis SK, Liu Y, Gibbons GH. Disparities in trends of hospitalization for potentially preventable chronic conditions among African Americans during the 1990s: implications and benchmarks. Am J Public Health. 2003;93(3):447-55.
21. Dilworth TJ, Mott D, Young H. Pharmacists' communication with Spanish-speaking patients: a review of the literature to establish an agenda for future research. Res Social Adm Pharm. 2009;5(2):108-20.
22. Gerber BS, Cano AI, Caceres ML, et al. A pharmacist and health promoter team to improve medication adherence among Latinos with diabetes. Ann Pharmacother. 2010;44(1):70-79.